Research Article
Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study
Table 2
Baseline characteristics of participants with and without cardiovascular drug treatment.
| Variable | No cardiovascular drug treatment () | Cardiovascular drug treatment () | value |
| Age, mean (SD), years | 55.58 (10.9) | 57.95 (10.63) | 0.092 | Sex, men | 226 (42.2%) | 34 (51.5%) | 0.188 | Smoking status | | | 0.495 | Yes | 105 (19.6%) | 17 (25.8%) | | Former | 260 (48.5%) | 29 (43.9%) | | Cholesterol, mean (SD), mmol/L | 6.38 (1.25) | 6.37 (1.12) | 0.927 | HDL-C, mean (SD), mmol/L | 1.39 (0.45) | 1.37 (0.43) | 0.858 | LDL-C, mean (SD), mmol/L | 4.41 (1.18) | 4.39 (1.03) | 0.888 | Triglycerides, mean (SD), mmol/L | 1.97 (1.5) | 1.91 (1.03) | 0.734 | Diastolic blood pressure, mean (SD), mmHg | 77.44 (9.62) | 79.85 (11.05) | 0.094 | Systolic blood pressure, mean (SD), mmHg | 134.66 (17.44) | 136.48 (19.66) | 0.473 | Hypertension, yes | 36.6% | 42.4% | 0.427 | Self-reported diabetes, yes | 39 (7.3%) | 12 (18.2%) | 0.006 | Familial CVD | | | 0.036 | Yes | 93 (17.4%) | 5 (7.6%) | | Do not know/missing value | 393 (73.3%) | 58 (87.9%) | | Cardiovascular risk score | 2.71 (3.42) | 3.92 (4.63) | 0.043 | Statins | | | 0.135 | Atorvastatin | 42 (7.6%) | 2 (4.5%) | | Rosuvastatin | 31 (5.9%) | 0 (0%) | | Simvastatin | 455 (84.9%) | 61 (92.4%) | | Other statin | 9 (1.7%) | 2 (3.0%) | | Dosea | | | 0.341 | Medium | 399 (63.2%) | 43 (65.2%) | | High | 31 (5.8%) | 1 (1.5%) | | Adherence | | | 0.077 | Low (0-80%) | 223 (41.6%) | 35 (53%) | |
|
|
Notes: aSee Table 1 for grouping of doses. Abbreviations: CVD: cardiovascular disease; CVE: cardiovascular event; H(L)DL-C: high- (low-) density lipoprotein cholesterol; SD: standard deviation. |